AstraZeneca PLC, which has been on fire for the inaccuracy of its data, announced Wednesday night an updated Phase 3 test data of its coronavirus vaccine, saying it is 76% effective in preventing COVID-19 symbolic.
AstraZeneca AZN,
The vaccine also said it was 100% effective against real diseases and hospitals, and for patients older than 65, it had 85% effectiveness against the virus.
“High-level positive results from the main study of the Phase III test of AZD1222 in the U.S. have confirmed the efficacy of vaccines according to the preliminary interim analysis announced Monday,” the company said in a statement. adds that it will submit data for emergency use permit to the U.S. Food and Drug Administration in the coming weeks.
On Monday, the British drugmaker said its vaccine had a 79% efficacy level. But Monday night, the U.S. National Institute for Allergies and Infectious Diseases said they were concerned that AstraZeneca had released “outdated information,” and that the company was accused of leaking data. .
At the time, the company said the figures were based on a “pre-determined interim analysis” and said it would share the results of a “major study with the latest efficiency data” on Thursday.
Earlier Wednesday, Dr. Anthony Fauci – head of the NIAID – said the AstraZeneca vaccine is good, even if its level of efficacy was not as high as it was originally. “At the end of the day, you know, when you look at the data, this is going to be a good vaccine,” Fauci said at the White House ‘s COVID-19 preparatory meeting on Wednesday.
“The main study is consistent with the previously released interim analysis, and confirms that our COVID-19 vaccine is very effective in adults,” said AstraZeneca chief executive Mene Pangalos in a statement Wednesday.
AstraZeneca vaccine has also been a cause for concern about possible blood clots. But last year the EU regulator said the drug was “safe and effective,” and in its statement on Wednesday night, the company said: “The vaccine has been well received, and no safety concerns have been raised. vaccine identification. ”
AstraZeneca data came from a study of more than 32,000 people.